Human Rights And Indigenous Peoples | Chemical & Engineering News
  • Jan. 30, pages 57 and 90, and March 5, page 61: Kimberly Prather is a professor at the University of California, San Diego, not UC Davis.

    March 5, page 55: Ute Deichmann is a she not a he, as stated in the article.

Volume 90 Issue 13 | pp. 6-7 | Letters
Issue Date: March 26, 2012

Human Rights And Indigenous Peoples

Department: Letters

In connection with Linda Wang’s “Bridging Cultures” article reporting on the AAAS Science & Human Rights Coalition meeting, I found the meeting to be useful (C&EN, Feb. 13, page 35). But just a few of the 150 participants were chemists.

The meeting emphasized that few scientists doing biomedical research consider traditional knowledge as intellectual property (IP) that should be protected and its benefits shared. That pharma sometimes comes into indigenous communities to gain empirical knowledge of decades-old traditional remedies and leaves to do further research and patent it is striking. Topics connecting bioprospecting with protecting IP rights of indigenous groups are by and large absent in ACS journals. One example is aspirin, which came from traditional knowledge as a starting point.

Wang’s article mentioned the United Nations General Assem­bly’s adoption of the Declaration on the Rights of Indigenous Peoples in 2007 for greater self-determination but did not suggest possible solutions. The declaration may lead to more equitable outcomes with regard to IP, but according to Megan Bang of the University of Washington, many injustices remain institutionalized and invisible.

Possible solutions include applying the Environmental Protection Agency’s environmental justice policy, or a nongovernmental organization could conduct negotiations with indigenous groups, with strategies comparable to the fair-trade movement, in which the NGO labels goods as being produced in a way that is both socially and environmentally responsible. No one would argue that protecting the IP rights to medicines associated with indigenous groups is a difficult task, and the cause may need a champion. Chemists could have a role in such a movement.

Joshua Rosenthal of the National Institutes of Health’s Fogarty International Center described a case 11 years ago, a rare instance where drug discovery researchers tried to include IP rights for local indigenous groups in Chiapas, Mexico. But the arrangement fell apart (disagreements among various group representatives), probably to the misfortune of all involved (Nature, DOI: 10.1038/414685a). Despite this outcome, chemists can embrace such responsibilities, seeking an enlightened view against biopiracy and patents that take indigenous knowledge, and instead seek protection and reciprocity.

By Alexander Greer
Brooklyn, N.Y.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment